🌟 AbbVie's Teliso-V Shows Promise in NSCLC! 🩺 In a significant development, AbbVie seeks accelerated approval for its c-Met antibody-drug conjugate (ADC), Teliso-V, following a promising update from the Luminosity trial. Teliso-V demonstrated an impressive 35% overall response rate in a specific subset of patients with advanced/metastatic nonsquamous non-small cell lung cancer (NSCLC) characterized by c-Met overexpression, representing approximately 25% of individuals with advanced EGFR wild type NSCLC. 📊 The Luminosity trial meticulously categorized patients based on c-Met expression levels, distinguishing between high and intermediate groups. Teliso-V exhibited a notable 35% response rate in the c-Met high group, with a slightly lower rate of 23% in the c-Met intermediate cohort. AbbVie's Chief Medical Officer, Dr Rupal Thakkar, highlights the even distribution of the targeted patient population between these two groups. #abbvie #TelisoV #LuminosityTrial #nsclc #MedicalAdvances #lifesciences
